United Therapeutics Corp. (UTHR) PT Raised to $245 at Jefferies

United Therapeutics (UTHR): Tyvaso DPI Approval and Label is 'Best Case Scenario', Brings 'Greater Pipeline Value' and 'Slower Market Share Erosion'

Shares of United Therapeutics (NASDAQ: UTHR) quickly climbed the list of Monday, May 23rd's top gainers and most active stocks, finishing the day nearly 12% higher, following midday news the company's Tyvaso DPI got an approval nod from the FDA.

The formal approval was confirmed by the United Therapeutics in this morning's press release, and... More

United Therapeutics Corp. (UTHR) PT Raised to $240 at Ladenburg Thalmann

Ladenburg Thalmann analyst Matthew Kaplan raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $240.00 (from $205.00) while maintaining a Buy rating.... More

United Therapeutics Corp. (UTHR) PT Raised to $255 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $255.00 (from $248.00) while maintaining a Buy rating.... More

Approved Tyvaso DPI Label is "Best Case Scenario" - Cowen Bullish on United Therapeutics (UTHR) Following FDA Approval

Cowen analyst Joseph Thome reiterated an Outperform rating and $250.00 price target on United Therapeutics Corp. (NASDAQ: UTHR), following the company's announcement of Tyvaso DPI approval.

The analyst comments: "Tyvaso DPI has been FDA approved for the treatment of PAH and PH-ILD.... More

United Therapeutics (UTHR) Announces FDA Approval of Tyvaso DPI

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug Administration (FDA) has approved Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH and PH-ILD.

Tyvaso DPI is one of the easiest ways for patients to administer... More

United Therapeutics Corp. (UTHR) PT Raised to $238 at JPMorgan

JPMorgan analyst Jessica Fye raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $238.00 (from $225.00) while maintaining a Overweight rating.... More

UPDATE: United Therapeutics Corp. (UTHR) PT Raised to $247 at Credit Suisse After Better Than Expected Tyvaso Indication

(Updated - May 24, 2022 7:07 AM EDT)

Credit Suisse analyst Tiago Fauth raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $247.00 (from $219.00) after the company won a clean Tyvaso DPI approval in group
1 and group 3 PH. The approval allows Tyvaso DPI to... More

MannKind (MNKD), Liquidia Technologies (LQDA) Trade in Opposite Directions on United Therapeutics' Approval

Action in MannKind (NASDAQ: MNKD) (gains) and Liquidia Technologies (NASDAQ: LQDA) (falls) said related to FDA approval of United Therapeutics' (NASDAQ: UTHR) Tyvaso DPI.

United Therapeutics (UTHR) now up 12.8% on earlier FDA headlines

United Therapeutics (NASDAQ: UTHR) now up 12.8% on earlier FDA headlines

United Therapeutics (UTHR) Tyvaso DPI approved, according to FDA - Bloomberg

United Therapeutics (NASDAQ: UTHR) Tyvaso DPI approved, according to FDA - Bloomberg. Citizens petition has been denied.